Difference between revisions of "Amrubicin (Calsed)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 12: | Line 12: | ||
==Patient drug information== | ==Patient drug information== | ||
No information available. | No information available. | ||
| + | |||
| + | ==History of changes in PMDA indication== | ||
| + | *2002-04-11: Initial approval for the treatment of [[Small cell lung cancer|small cell]] and [[non-small cell lung cancer]]. | ||
==Also known as== | ==Also known as== | ||
Revision as of 15:50, 5 May 2023
General information
Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
No information available.
History of changes in PMDA indication
- 2002-04-11: Initial approval for the treatment of small cell and non-small cell lung cancer.
Also known as
- Code name: SM-5887
- Generic names: AMR, amrubicin HCI
- Brand name: Calsed